Functional and prognostic role of ZAP-70 in chronic lymphocytic leukaemia

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 6, 2005, Pages 1165-1178

  Hamblin, Angela D ^a   Hamblin, Terry J ^a  

^a ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

B cell receptor (BCR); CD38; Chronic lymphocytic leukaemia (CLL); Flow cytometry; Heat shock protein; IgV genes; Immunophenotype; Prognostic factor; Tyrosine kinase; ZAP 70

Indexed keywords

1 (2 PHENOL) 2 NAPHTHOL DERIVATIVE; 17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 2 NAPHTHOL; CD23 ANTIGEN; CD38 ANTIGEN; CHAPERONE; DISINTEGRIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN; LIPOPROTEIN LIPASE; METALLOPROTEINASE; PROTEIN ANTIBODY; PROTEIN INHIBITOR; PROTEIN KINASE ZAP 70; UNCLASSIFIED DRUG;

B LYMPHOCYTE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HYPERGLYCEMIA; IMMUNOGLOBULIN GENE; IMMUNOGLOBULIN VARIABLE REGION; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

B-LYMPHOCYTES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 28844449552     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.6.1165     Document Type: Review

References (139)

1. HAMBLIN TJ, DAVIS Z, GARDINER A, OSCIER DG, STEVENSON FK: Unmucated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood (1999) 94:1848-1854.
2. DAMLE RN, WASIL T, FAIS F et al.: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood (1999) 94:1840-1847.
3. HAMBLIN TJ, ORCHARD JA, DAVIS Z, GARDINER A, OSCIER DG, STEVENSON FK: Immunoglobulin V genes and CD38 expression in CLL. Blood (2000) 95:2455-2457.
4. ROSENWALD A, ALIZADEH AA, WIDHOPF G et al.: Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J. Exp. Med. (2001) 194:1639-1647.
5. KLEIN U, TU Y, STOLOVITZKY GA et al.: Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J. Exp. Med. (2001) 194:1625-1638.
6. CALIGARIS-CAPPIO F, HAMBLIN TJ: B-cell chronic lymphocytic leukemia: a bird of a different feather. J. Clin. Oncol. (1999) 17:399-408.
7. BENNETT JM, CATOVSKY D, DANIEL MT et al.: French-American-British (FAB) Cooperative Group. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. J. Clin. Pathol. (1989) 42:567-584.
8. MATUTES E, OSCIER DG, GARCIA-MARCO J et al.: Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br. J. Haematol. (1996) 92:382-388.
9. ROZMAN C, HERNANDEZ-NIETO L, MONTSERRAT E, BRUGUES R: Prognostic significance of bone marrow patterns in chronic lymphocytic leukaemia. Br. J. Haematol. (1981) 47:529-537.
10. SCHMID C, ISAACSON PG: Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study. Histopathology (1994) 24:445-51.
11. TERNYNCK T, DIAGHIERO G, FALLEZOU J, BINET JL: Comparison of normal and CLL lymphocyte surface Ig determinants using peroxidase-labeled antibodies. I. Detection and quantitation of light chain determinants. Blood (1974) 43:789-795.
12. ZOMAS AP, MATUTES E, MORILLA R et al.: Expression of immunoglobulin-associated protein B29 in B cell disorders with the monoclonal antibody SN8 (CD79b). Leukemia (1996) 10:1966-1970.
13. SERKE S, SCHWANER I, YORDANOVA M, SZCZEPEK A, HUHN D: Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses. Cytometry (2001) 46:98-104.
14. POLYAK MJ, AYER LM, SZCZEPEK AJ, DEANS JP: A cholesterol-dependent CD20 epitope detected by the FMC7 antibody. Leukemia (2003) 17:1384-1389.
15. MOLICA S, LEVATO D, DATILLO A, MANNELLA A: Clinico-prognostic relevance of quantitative immunophenotyping in B-cell chronic lymphocytic leukemia with emphasis on the expression of CD20 antigen and surface immunoglobulins. Eur. J. Haematol. (1998) 60:47-52.
16. CATOVSKY D, CHERCHI M, BROOKS J, BRADLEY J, ZOLA H: Heterogeneity of B cell leukemias demonstrated by the monoclonal antibody FMC7. Blood (1981) 33:173-177.
17. MATUTES E, OWUSU-ANKOMAH K, MORILLA R et al.: The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia (1994) 10:1640-5.
18. COLOMBO M, DONO M, CUTRONA G et al.: Subpopulations of human B cells and their elationship with the B-CLL cell. Leuk. Lymphoma (2005) 46(Suppl. 1):S3.
19. DAMESHEK W. Chronic lymphocytic leukemia - an accumulative disease of immunologically incompetent lymphocytes. Blood (1967) 24:566-584.
20. GALTON DAG: The pathogenesis of chronic lymphocytic leukaemia. Can. Med. Assoc. J. (1966) 94:1005-1010.
21. PANAYIOTIDIS P, JONES D, GANESHAGURU K, FORONI L, HOFFBRAND AV. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br. J. Haematol. (1996) 92:97-103.
22. LAGNEAUX L, DELFORGE A, BRON D, DE BRUYN C, STRYCKMANS P: Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood (1998) 91:2387-96.
23. BURGER JA, TSUKADA N, BURGER M, ZVAIFLER NJ, DELE'AQUILA M, KIPPS TJ: Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood (2000) 96:2655-2663.
24. FADERL S, KEATING MJ, DO KA et al.: Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia (2002) 16:1045-1052.
25. MOLICA S, DATTILO A, GIULINO C, LEVATO D, LEVATO L: Increased bcl-2/bax ratio in B-cell chronic lymphocytic leukemia is associated with a progressive pattern of disease. Haematologica (1998) 83:1122-1124.
26. BELLOSILLO B, DALMAU M, COLOMER D, GIL J: Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells. Blood (1997) 89:3378-3384.
27. LEONI I, CHAO Q, COTTAM H et al.: Induction of an apoptotic program in cell-free extracts by 2-chloro-2′-deoxyadenosine 5′-triphosphate and cytochrome c. Proc. Natl. Acad. Sci. USA (1998) 95:9567-9571.
28. KITADA S, ANDERSEN J, AKAR S et al.: Evidence of apoptosis regulating proteins in chronic lymphocytic leukemia; correlations with in vitro and in vivo chemoresponses. Blood (1998) 91:3379-3389
29. ORCHARD JA, OSCIER DG: Prognostic value of Ki 67 and cell cycle analysis in chronic lymphocytic leukaemia. Br. J. Haematol. (1996) 93:116.
30. DRACH J, GATTRINGER C, GLASSL H, SCHWARTING R, STEIN H, HUBER H: Simultaneous flowcytometric analysis of surface markers and nuclear Ki-67 antigen in leukemia and lymphoma. Cytometry (1989) 10:743-749.
31. ORFAO A, CIUDAD J, GONZALEZ M et al: Prognostic value of S-phase white blood cell count in B-cell chronic lymphocytic leukaemia. Leukemia (1992) 6:47-51.
32. CORDONE I, MATUTES E, CATOVSKY D: Monoclonal antibody Ki-67 identifies B and T cells in cycle in chronic lymphocytic leukaemia. Leukemia (1992) 6:902-906.
33. DEL GIGLIO A, O'BRIEN S, FORD RJ JR et al.: Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukaemia (CLL). Leuk. Lymphoma (1993) 10:265-271.
34. DAMLE RN, BATLIWALLA FM, GHIOTTO F et al.: Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood (2004) 103:375-382.
35. PILERI SA, ASCANI S, SABATTINI E: The pathologist's view point. Part I-indolent lymphomas. Haematologica (2000) 85:1291-307.
36. ZIMMERMAN TS, GODWIN HA, PERRY S: Studies of leukocyte kinetics in chronic lymphocytic leukemia. Blood (1968) 31:277-291.
37. SCHIFFER LM, CHANANA AD, CRONKITE EP: Lymphocyte kinetics in chronic lymphocytic leukaemia (CLL) studied by ECIB. Br. J. Haematol. (1969) 17:408.
38. SIMONSSON B, NILSSON K: 3H-thymidine uptake in chronic lymphocytic leukaemia cells. Scand. J. Haematol. (1980) 24:169-73.
39. DORMER P, THEML H, LAU B: Chronic lymphocytic leukemia: a proliferative or accumulative disorder? Leuk. Res. (1983) 7:1-10.
40. MESSMER BT, MESSMER D, ALLEN SL et al.: In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J. Clin. Invest. (2005) 115:755-764.
41. JULIUSSON G, OSCIER DG, FITCHETT M et al.: Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N. Engl. J. Med. (1990) 323:720-724.
42. DOHNER H, STILGENBAUER S, BENNER A et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. (2000) 343:1910-1916.
43. CALIN GA, LIU CG, SHIMIZU M et al.: MicroRNA profiling reveals distinct signatures in B-cell chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA (2004) 101:11755-11760.
44. CIMMINO A, CALLIN GA, FABBRI M et al.: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA (2005) 102:13944-13949.
45. DOHNER H, STILGENBAUER S, JAMES M et al.: 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterised by extensive nodal involvement and inferior prognosis. Blood (1997) 89:2516-2522.
46. LIN K, SHERRINGTON PD, DENNIS M, MATRAI Z, CAWLEY JC, PETTITT AR: Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood (2002) 100:1404-1409.
47. AUSTEN B, PODINOVSKAIA M, ALMOND C et al.: CLL tumours with a deletion of 11q form two functional subgroups based on the mutations status of the remaining ATM allele. Leuk. Lymphoma (2005) 46(Suppl. 1):S57.
48. DOHNER H, FISCHER K, BENTZ M et al.: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood (1995) 85:1580-1589.
49. OSCIER DG, GARDINER AC, MOULD SJ et al.: Multivariate analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood (2002) 100:1177-1184.
50. H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood (2002) 100:1410-1416.
51. CUNEO A, RIGOLIN GM, BIGONI R et al.: Chronic lymphocytic leukemia with 6q-shows distinct hematological features and intermediate prognosis. Leukemia (2004) 18:476-483.
52. TONEGAWA S: Somatic generation of antibody diversity. Nature (1983) 302-575-581.
53. ALT FW, OLTZ EM, YOUNG F, GORMAN J, TACCIOLI G, CHEN J: VDJ recombination. Immunol. Today (1992) 13:306-314.
54. LEWIS S, GELLERT M: The mechanism of antigen receptor gene assembly. Cell (1989) 59:585-588.
55. DESIDERIO SV, YANCOPOULOS GD, PASKIND M et al.: Insertion of N regions into heavy chain genes is correlated with the expression of terminal deoxytransferase in B cells. Nature (1984) 311:752-755
56. MACLENNAN IC: Germinal centers. Ann. Rev Immunol. (1994) 12:117-139.
57. CALIGARIS-CAPPIO FB: Chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood (1996) 87:2615-20.
58. SCHROEDER HW JR, DIGHIERO G: The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol. Today (1994) 15:288-294.
59. HAMBLIN TJ, DAVIES Z, OSCIER DG, STEVENSON FK: In chronic lymphocytic leukemias germline configuration of immunoglobulin heavy chain genes is associated with a more aggressive form of the disease. Blood (1998) 92(Suppl. 1):515a.
60. H genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood (2000) 95:377-378.
61. BAHLER DW, AGUILERA NS, CHEN CC et al.: Histological and immunoglobulin VH gene analysis of interfollicular small lymphocytic lymphoma provides evidence for two types. Am. J. Pathol. (2000) 157:1063-1070.
62. JELINEK DF, TSCHUMPER RC, GEYER SM et al.: Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br. J. Haematol. (2001) 115:854-861.
63. STILGENBAUER S, BULLINGER L, LICHTER P, DOHNER H: German CLL Study Group (GCLLSG). Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia (2002) 16:993-1007.
64. HAMBLIN TJ: Chronic Lymphocytic Leukaemia: One Disease or Two? Ann. Hematol. (2002) 81:299-303.
65. H3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood (2002) 99:2262-2264.
66. TOBIN G, THUNBERG U, JOHNSON A et al.: Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted V lambda 2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood (2003) 101:4952-4957.
67. CHIORAZZI N, FERRARINI M: B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Ann. Rev. Immunol. (2003) 21:841-894.
68. MESSMER BT, ALBESIANO E, EFREMOV DG et al.: Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J. Exp. Med. (2004) 200:519-525.
69. TOBIN G, THUNBERG U, KARLSSON K et al.: Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood (2004) 104:2879-2885.
70. HERVE M, XU K, NG YS et al.: Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J. Clin. Invest. (2005) 115:1636-1643.
71. CERRONI L, ZOCHLING N, PUTZ B, KERL H: Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J. Cutan. Pathol. (1997) 24:457-461.
72. WOTHERSPOON AC, ORTIZ-HIDALGO C, FALZON MR, ISAACSON PG: Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet (1991) 338:1175-1176.
73. STEVENSON FK, CALIGARIS-CAPPIO F: Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood (2004) 103:4389-4395.
74. PASCUAL V, VICTOR K, SPELLERBERG M, HAMBLIN TJ, STEVENSON FK, CAPRA JD: VH restriction among human cold agglutinins: The VH4-21 gene segment is required to encode anti-I and anti-i specificities. J. Immunol. (1992) 149:2337-2334.
75. HOWARD M, GRIMALDI JC, BAZAN JF et al.: Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science (1993) 262:1056-1059.
76. MALAVASI F, FUNARO A, ROGGERO S, HORENSTEIN A, CALOSSO L, MEHTA K: Human CD38: a glycoprotein in search of a function. Immunol Today (1994) 15:95-97.
77. DEAGLIO S, MEHTA K, MALAVASI F: Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk. Res. (2001) 25:1-12.
78. BAUVOIS B, DURANT L, LABOUREAU J et al.: Upregulation of CD38 gene expression in leukemic B cells by interferon types I and II. J. Interferon Cytokine Res. (1999) 19:1059-1066.
79. HAMBLIN TJ, ORCHARD JA, IBBOTSON RE et al.: CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood (2002) 99:1023-1029.
80. BURGER JA, TSUKADA N, BURGER M, ZVAIFLER NJ, DELE'AQUILA M, KIPPS TJ: Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood (2000) 96:2655-2663.
81. DEAGLIO S, VAISITTI T, BERGUI L et al.: CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood (2005) 105:3042-3050.
82. DEAGLIO S, CAPOBIANCO A, BERGUI L et al.: CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood (2003) 102:2146-2155.
83. DEAGLIO S, VAISITTI T, MALAVASI F: CD38 ligation in B-Chronic Lymphocytic Leukemia cells induced sequential tyrosine phosphorylation of ZAP-70, PLC-γ2 and ERK1/2 proteins. Blood (2004) 104(Suppl. 1):959a
84. KUROYAMA H, IKEDA T, KASAI M et al.: Identification of a novel isoform of ZAP-70, truncated ZAP kinase. Biochem. Biophys. Res. Commun. (2004) 315:935-941.
85. NEL AE: T-cell activation through the antigen receptor. Part 1: signaling components, signaling pathways, and signal integration at he T-cell antigen receptor synapse. J. Allergy Clin. Immunol. (2002) 109:758-770.
86. CHAN AC, VAN OERS NS, TRAN A et al.: Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. J. Immunol. (1994) 152:4758-4766.
87. KUROSAKI T: Regulation of B cell fates by BCR signaling components. Curr. Opin. Immunol. (2002) 14:341-347.
88. SCHWEIGHOFFER E, VANES L, MATHIOT A, NAKAMURA T, TYBULEWICZ VL: Unexpected requirement for ZAP-70 in pre-B cell development and allelic exclusion. Immunity (2003) 18:523-533.
89. HARDY RR, HAYAKAWA K: B cell developmental pathways. Ann. Rev. Immunol. (2001) 19:595-621.
90. ROLINK AG, SCHANIEL C, ANDERSSON J, MECHERS F: Selection events operating at various stages in B cell development. Curr. Opin. Immunol. (2001) 13:202-207.
91. NOLZ JC, TSCHUMPER RC, PITTNER BT, DARCE JR, KAY NE, JELINEK DF: ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. Leukemia (2005) 19:1018-1024.
92. LATOUR S, CHOW LML, VEILLETTE A: Differential intrinsic enzymatic activity of Syk and ZAP-70 protein-kinases. J. Biol. Chem. (1996) 271:22782-22790.
93. CHEN L, WIDHOPF G, HUYNH L et al.: Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood (2002) 100:4609-4614.
94. LANHAM S, HAMBLIN T, OSCIER D et al.: Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood (2003) 101:1087-1093
95. ZUPO S, MASSARA R, DONO M et al.: Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. Blood (2000) 95:1199-206.
96. CHEN L, APGAR J, HUYNH L et al.: ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood (2005) 105:2036-2041.
97. CRAGG MS, CHAN HTC, FOX MD et al.: The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signalling for apoptosis. Blood (2002) 100:3068-3076.
98. FUKUDA T, TOY TL, RASSENTI LZ, RAI KR, KIPPS TJ: ICOS is induced by B cell receptor signalling on chronic lymphocytic leukemia B cells. Blood (2004) 104(Suppl 1):969a.
99. KAMAL A, THAO L, SENSINTAFFAR J et al.: A high-affinity conformation of Hsp90 confers rumor selectivity on Hsp inhibitors. Nature (2003) 425:407-410.
100. TIAN ZQ, LIU Y, ZHANG D et al.: Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg. Med. Chem. (2004) 12:5317-5329.
101. CASTRO JE, PRADA CE, LORIA O et al.: ZAP-70 is a novel conditional Heat shock protein 90 (Hsp90)-client protein: Inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis and impaired signaling in chronic lymphocytic leukemia. Blood (2005) 106:2606-2512.
102. SUP SJ, DOMIATI-SAAD R, KELLEY TW, STEINLE R, ZHAO X, HIS ED: ZAP-70 expression in B-cell hematolgic malignancy is not limited to CLL/SLL. Am. J. Clin. Pathol. (2004) 122:582-587.
103. ADMIRAND JH, RASSIDAKIS GZ, ABRUZZO LV, VALBUENA JR, JONES D, MEDEIROS LJ: Immunohistochemical detaection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. Mol. Pathol. (2004) 17:954-961.
104. CARRERAS J, VILLAMOR N, COLOMO L et al.: Immunohistochemical analysis of ZAP-70 expression in lymphoid neoplasms. J. Pathol. (2005) 205:507-513.
105. WIESTNER A, ROSENWALD A, BARRY T et al.: ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with immutated immunoglobulin genes, inferior clinical outcome and distinct gene expression profile. Blood (2003) 101:4944-4951.
106. CRESPO M, BOSCH F, VILLAMOR N et al.: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. (2003) 348:1764-1775.
107. ORCHARD JA, IBBOTSON RE, DAVIS Z et al.: ZAP-70 expression by flow cytometry is a good prognostic marker in CLL and a potential surrogate for immunoglobulin VH gene mutations. Lancet (2004) 363:105-111.
108. RASSENTI LZ, HUYNH L, TOY TL et al.: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N. Engl. J. Med. (2004) 351:893-901.
109. ARMITAGE P, BERRY G: Statistical Methods in Medical Research. Blackwell Science, Oxford, United Kingdom. (1987).
110. YOUDEN WJ: Index for rating diagnostic tests. Cancer (1950) 3:32-35.
111. STILGENBAUER S: Chronic lymphocytic leukemia and high risk genetics: disease progression and resistance to treatment. Leuk. Lymphoma (2005) 46(Suppl. 1):S6.
112. CHESON BD, BENNETT JM, GREVER M et al.: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 87:4990-4997.
113. LETESTU R, BOECKX N, BOETTCHER S et al.: Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: a multicentric international harmonization process. Leuk. Lymphoma (2005) 46:S47.
114. VILLAMOR N, CRESPO M, BOSCH F et al.: ZAP-70 expression remains stable during the course of chronic lymphocytic leukemia. Leuk. Lymphoma (2005) 46:S43.
115. RAI KR, SAWITSKY A, CRONKITE ER, CHANANA AD, LEVY RN, PASTERNACK BS: Clinical staging of chronic lymphocytic leukemia. Blood (1975) 46:219-234.
116. BINET J-L, LEPORIER M, DIGHIERO G et al.: A clinical staging system for chronic lymphocytic leukemia. Cancer (1977) 40:855-864.
117. CLL TRIALISTS' COLLABORATIVE GROUP: Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J. Natl Cancer Inst. (1999) 91:861-868.
118. MONTSERRAT E, SANCHEZ-BISONO J, VINOLAS N, ROZMAN C: Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br. J. Haematol. (1986) 62:567-575.
119. HALLEK M, LANGENMAYER I, NERL C et al.: Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, non-smoldering chronic lymphocytic leukemia. Blood (1999) 93:1732-1737.
120. MONTILLO M, HAMBLIN T, HALLEK M, MONTSERRAT E, MORRA E: Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica (2005) 90:391-399.
121. SARFATI M, CHEVET S, CHASTANG C et al.: Prognostic importance of serum levels of CD23 in chronic lymphocytic leukemia. Blood (1996) 88:4259-4264.
122. MOLICA S, LEVATO D, DELL'OLIO M et al.: Cellular expression and serum circulating levels of CD23 in B-cell chronic lymphocytic leukemia. Implications for prognosis. Haematologica (1996) 81:428-433.
123. KANTARJIAN HM, SMITH T, ESTEY E et al.: Prognostic significance of elevated serum beta-2-microglobulin levels in adult acute lymphocytic leukemia. Am. J. Med. (1992) 93:599-604.
124. IBRAHIM S, KEATING M, DO KA et al.: CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood (2001) 98:181-186.
125. SCHROERS R, GRIESEINGER F, TRUMPER L et al.: Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia (2005) 19:750-758.
126. BOSCH F, CRESPO M, VILLAMOR N et al.: Clinical characteristics and outcome of a large series of patients with chronic lymphocytic leukemia (CLL) according to ZAP-70 expression. Blood (2004) 104(Suppl. 1):14a.
127. CATOVSKY D: CLL4 trial. NCRI Haematological Oncology Study Group Annual Review (2005):5-19.
128. HAMBLIN TJ, GARDINER AC, MOULD SJ et al.: Can we predict which patients with early stage CLL will progress and require treatment? Leuk. Lymphoma (2005) 46:S46.
129. MARTI GE, RAWSTRON AC, GHIA P et al.: Diagnostic criteria for monoclonal B-cell lymphocytosis. Br. J. Haematol. (2005) 130:325-332
130. HALLEK M: Risk adapted management of chronic lymphocytic leukemia: update on the co-operative trials of the German Chronic Lymphocytic Leukemia Study Group. Haematologica (2003) 88(Suppl. 17):26-30.
131. OPPEZZO P, VASCONCELOS Y, SETTEGRANA C: The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood (2005) 106:650-657.
132. NUCKEL H, REBMANN V, DURIG J, DUHESEN U, GROSSE-WILDE: HLA-G expression is associated with an unfavorable outcome and immunodeficiency and immunodeficiency in chronic lymphocytic leukemia. Blood (2005) 105:1694-1698.
133. O'DWYER ME, DRUKER BJ: STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. Lancet Oncol. (2000) 1:207-211.
134. BAGATELL R, WHITESELL L: Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol. Cancer Ther. (2004) 3:1021-1030.
135. PARK JW, YEH MW, WONG MG et al.: The heat shock protein 90-binding antibiotic geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines. J. Clin. Enaocrinol. Metab. (2003) 88:3346-3353.
136. BRAGA-BASARIA M, HARDY E, GOTTFRIED R, BURMAN KD, SAJI M, RINGEL MD: 17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels. J. Clin. Endocrinol. Metab. (2004) 89:2982-2988.
137. ERLICHMAN C, TOFT D, REID J et al.: A Phase I trial of 17-allylamino-gelanamycin (17AAG) in patients with advanced cancer. J. Clin. Oncol (2004) 22:14S:3030a.
138. IVY PS, SCHOENFELDT M: Clinical trials referral resource. Current clinical trials of 17-AG and 17-DMAG. Oncology (2004) 18:610, 615, 619-620.
139. BARRIL X, BROUGH P, DRYSDALE M et al.: Structure-based discovery of a new class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett. (2005) (Sep 29; Epub ahead of print).